Phytoestrogen tissue levels in benign prostatic hyperplasia and prostate cancer and their association with prostatic diseases

Brössner, Clemens; Petritsch, Karin; Fink, Klaus; Auprich, Marco; Madersbacher, Stephan; Adlercreutz, Herman; Rehak, Peter; Petritsch, P.

doi:10.1016/j.urology.2004.04.046

Cited by 32 publications

(33 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…There is evidence that Asian cultures have lower prostate cancer rates compared to Western cultures [9][10][11][12]25]. Furthermore, when data is stratified examining individuals that produce equol naturally after soy consumption suggest that lower cancer rates are due to the beneficial influence of this isoflavonoid molecule [31].…”

Section: Discussionmentioning

confidence: 99%

“…Interest in complementary and alternative medicines (CAM) for BPH increased after epidemiological and traditional hypothesis-driven scientific studies showed a lower incidence of BPH and prostate cancer in Asians compared to persons in Western countries [9][10][11][12]. This caused a paradigm-shift to explore other known and/or previously unknown "natural" treatments for BPH that have reduced side effects.…”

Section: Introductionmentioning

confidence: 99%

“…Increased research attention directed toward the isoflavonoids in the last 20 years where genistein was first thought to be responsible for improved prostate health [9,11], however, since the equol hypothesis was proposed in the late 1990s there has been increased focus on this isoflavonoid molecule [18].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Severe & Moderate BPH Symptoms in Mid-Aged Men Improve with Isoflavonoid-Equol Treatment: Pilot Intervention Study

Lephart¹

2013

OJU

View full text Add to dashboard Cite

Benign prostatic hyperplasia (BPH) is the pathological cellular progression of glandular proliferation associated with aging. Current available treatment options for BPH have limitations and various adverse effects. Equol is a polyphenolic/isoflavonoid molecule derived from intestinal metabolism, dairy and dietary plant sources. It has the unique characteristic to bind specifically 5α-dihydrotestosterone (5α-DHT) by sequestering 5α-DHT from the androgen receptor, thus decreasing androgen hormone actions to improve prostate health by acting as a selective androgen modulator (SAM). It also has affinity for estrogen related receptor gamma (ERR-γ) and estrogen receptor beta (ER-β) within the prostate that is known to improve male health via selective estrogen receptor modulatory (SERM) activities to decrease inflammation, cellular proliferation and carcinogenesis. We investigated the possible clinical efficacy of equol on the symptoms associated with benign prostatic hyperplasia (BPH) in this study. Materials and Methods: We performed a pilot intervention study evaluating the effects of low dose oral equol supplement (6 mg, twice a day with meals) for 4 weeks in a total of 18 men (49 -60 years old) with moderate or severe BPH. Subjects included in the study: gave informed consent, underwent a physical examination and verified their BPH symptoms as measured by the International Prostate Symptom Scores (IPSS) and then were assigned to the moderate or severe BPH groups based upon their total IPSS index. All adverse events were reported. The primary efficacy measure was the IPSS parameters comparing baseline to 2 and 4 week IPSS indices. Blood samples were collected at the baseline and 4th week visits that served as secondary efficacy parameters that included testosterone, 5α-DHT and general blood chemistries along with cardiac and hepatic function panels. Results: Low dose equol positively improved moderate to severe BPH symptoms according to the IPSS indices. In moderately symptomatic men (n = 10) 5 out of 7 of the IPSS parameters significantly improved by 4 weeks of equol treatment. In severely symptomatic men (n = 8) all 7 of the IPSS parameters significantly improved with 4 weeks of equol treatment. There were no significant changes in androgen levels, general blood chemistries or cardiac and hepatic function parameters. Although, 5α-DHT levels declined by 21% in severely symptomatic men (from baseline vs 4 week values). Conclusion: These findings suggest that equol may provide a well tolerated and rapid beneficial therapy for BPH that can be used alone or in combination with current pharmaceutical therapies. The beneficial clinical efficacy of equol observed in this study may be due to the multiple positive biological actions that are not present in current pharmaceutical treatments.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Severe & Moderate BPH Symptoms in Mid-Aged Men Improve with Isoflavonoid-Equol Treatment: Pilot Intervention Study

Lephart¹

2013

OJU

View full text Add to dashboard Cite

show abstract

“…Epidemiological and laboratory studies have demonstrated that several nutrients, including isoflavones, could induce apoptosis and suppress the formation and growth of human cancers including prostate cancer (7)(8)(9)(10)(11)(12)(13)(14). Population studies have consistently reported lower incidence of clinically evident disease in populations consuming isoflavones.…”

Section: Introductionmentioning

confidence: 99%

“…Population studies have consistently reported lower incidence of clinically evident disease in populations consuming isoflavones. An inverse relationship between dietary intake, plasma (8)(9)(10)(11)(12)(13), and prostatic fluid (14) concentrations of isoflavones and the incidence of prostate cancer and benign prostatic hyperplasia (BPH) has been observed in these populations, demonstrating the potential role of isoflavones in mediating epigenetic effects. In vitro data have consistently shown that genistein modulates cell proliferation, (15)(16)(17)(18)(19), angiogenesis (20)(21), tumor cell invasion and tumor metastasis (17,22,23) cell cycle regulation (26), antioxidant (22,25), and induction of apoptotic cell death (26), demonstrating that isoflavones have several cellular effects that are both genomic and nongenomic.…”

Section: Introductionmentioning

confidence: 99%

A Phase II Randomized, Placebo-Controlled Clinical Trial of Purified Isoflavones in Modulating Steroid Hormones in Men Diagnosed With Localized Prostate Cancer

Kumar

Krischer

Allen

et al. 2007

Nutrition and Cancer

View full text Add to dashboard Cite

Our purpose was to evaluate the safety and effectiveness of purified isoflavones in producing an increase in plasma isoflavones and a corresponding change in serum sex hormone binding globulin (SHBG) and steroid hormone levels in men diagnosed with early stage prostate cancer. In this Phase II randomized, double-blinded, placebo-controlled trial, 53 prostate cancer patients with a Gleason score of 6 or below were supplemented with 80 mg purified isoflavones or placebo for 12 weeks. Changes in plasma isoflavones, serum steroid hormones, and safety markers were analyzed from baseline to 12 wk. A total of 50 subjects completed the study. Although significant increases in plasma isoflavones (P < 0.001) was observed with no clinical toxicity, the corresponding modulation of serum SHBG, total estradiol, and testosterone in the isoflavone-treated group compared to men receiving placebo was nonsignificant. Increasing plasma isoflavones failed to produce a corresponding modulation of serum steroid hormone levels in men with localized prostate cancer. The study establishes the need to explore other potential mechanisms by which prolonged and consistent purified isoflavone consumption may modulate prostate cancer risk.

show abstract

Plasma and prostate phytoestrogen concentrations in prostate cancer patients after oral phytoestogen supplementation

et al. 2005

View full text Add to dashboard Cite

show abstract

Phytoestrogen tissue levels in benign prostatic hyperplasia and prostate cancer and their association with prostatic diseases

Cited by 32 publications

References 21 publications

Severe & Moderate BPH Symptoms in Mid-Aged Men Improve with Isoflavonoid-Equol Treatment: Pilot Intervention Study

Severe & Moderate BPH Symptoms in Mid-Aged Men Improve with Isoflavonoid-Equol Treatment: Pilot Intervention Study

A Phase II Randomized, Placebo-Controlled Clinical Trial of Purified Isoflavones in Modulating Steroid Hormones in Men Diagnosed With Localized Prostate Cancer

Plasma and prostate phytoestrogen concentrations in prostate cancer patients after oral phytoestogen supplementation

Contact Info

Product

Resources

About

Phytoestrogen tissue levels in benign prostatic hyperplasia and prostate cancer and their association with prostatic diseases

Cited by 32 publications

References 21 publications

Severe &amp; Moderate BPH Symptoms in Mid-Aged Men Improve with Isoflavonoid-Equol Treatment: Pilot Intervention Study

Severe &amp; Moderate BPH Symptoms in Mid-Aged Men Improve with Isoflavonoid-Equol Treatment: Pilot Intervention Study

A Phase II Randomized, Placebo-Controlled Clinical Trial of Purified Isoflavones in Modulating Steroid Hormones in Men Diagnosed With Localized Prostate Cancer

Plasma and prostate phytoestrogen concentrations in prostate cancer patients after oral phytoestogen supplementation

Contact Info

Product

Resources

About

Severe & Moderate BPH Symptoms in Mid-Aged Men Improve with Isoflavonoid-Equol Treatment: Pilot Intervention Study

Severe & Moderate BPH Symptoms in Mid-Aged Men Improve with Isoflavonoid-Equol Treatment: Pilot Intervention Study